The materials for LENVIMA® (lenvatinib) capsules and HALAVEN® (eribulin mesylate) injection in this virtual exhibit are approved for use only in the United States. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to your local prescribing information and consult directly the local affiliate of the relevant company to address any questions.
At Eisai, it is our privilege and responsibility to put patients and their families first – providing access to the medicines they need; sharing our innovative research and development programs; and supporting the pioneers in patient advocacy and the healthcare providers who do so much for the metastatic and marginalized communities we seek to serve.
We recognize the mental, emotional, and physical challenges people living with cancer and their loved ones face each day. The novel COVID-19 virus has made those hardships even greater now. Our human health care mission means we remain committed to our responsibilities. We will not hesitate to evolve and do what is right to meet the needs of patients and the health care community.